Virax Biolabs Group Overview
Get informed when a big investor buys or sells
+ Follow-146.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Virax Biolabs Group (VRAX) currently reports a ROE of -146.29%. That is below the sector sector average of 11.85%. Use the charts on this page to explore Virax Biolabs Group's ROE history and peer comparisons.
Virax Biolabs Group's ROE of -146.29% is lower than the its sector sector average of 11.85%. That is roughly 1334.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Virax Biolabs Group's current -146.29% should be judged against industry norms (sector average: 11.85%) and against VRAX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -146.29%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.85%. From there, open related valuation or income-statement pages for Virax Biolabs Group, and consider following VRAX for alerts when major investors trade the stock.
